# EDGAR Filing Document

**Accession Number:** 0001017110
**File Stem:** 0000000000-23-002096
**Filing Date:** 2023-3
**Character Count:** 2856
**Document Hash:** d011420f071bc187781cfe459bdb7eb7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-23-002096.hdr.sgml**: 20230330

**ACCESSION NUMBER**: 0000000000-23-002096

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230302

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GENETHERA INC
- **CENTRAL INDEX KEY:** 0001017110
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 650622463
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD

**BUSINESS ADDRESS:**
- **STREET 1:** 3051 W 105TH AVENUE
- **STREET 2:** UNIT 350251
- **CITY:** WESTMINSTER
- **STATE:** CO
- **ZIP:** 80031
- **BUSINESS PHONE:** 720-587-5100

**MAIL ADDRESS:**
- **STREET 1:** 3051 W 105TH AVENUE
- **STREET 2:** UNIT 350251
- **CITY:** WESTMINSTER
- **STATE:** CO
- **ZIP:** 80031

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** HAND BRAND DISTRIBUTION INC
- **DATE OF NAME CHANGE:** 19990818
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001477932-22-002272

## Text-Extract

```

United States securities and exchange commission logo

                     March 2, 2023

       Tanya Irizarry
       Chief Financial Officer
       GeneThera Inc.
       3051 W. 105th Ave. #350251
       Westminster, CO 80035

                                                        Re: GeneThera Inc.
                                                            Form 10-K for the
Fiscal Year Ended December 31, 2021
                                                            Filed April 14,
2022
                                                            File No. 000-27237

       Dear Tanya Irizarry:

              We have completed our review of your filing. We remind you that
the company and its
       management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding
       any review, comments, action or absence of action by the staff.

                     Sincerely,

                     Division of Corporation Finance

                     Office of Life Sciences

```

### Attached PDF Documents

**Attachment 1:** `filename1`

![img-0.jpeg](img-0.jpeg)

DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

March 2, 2023

Tanya Irizarry
Chief Financial Officer
GeneThera Inc.
3051 W. 105th Ave. #350251
Westminster, CO 80035

Re: GeneThera Inc.

Form 10-K for the Fiscal Year Ended December 31, 2021

Filed April 14, 2022

File No. 000-27237

Dear Tanya Irizarry:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance
Office of Life Sciences